RARE OR GENETIC

5 minute read

Mar. 1, 2022

Mitapivat, Pacritinib, and Sutimlimab Among FDA Approvals in February 2022

Authors:

Vinicius Teixeira,

Jennifer Huen

Other articles you may be interested in